KDC-MN-1302 – Kodiac biolabs

Plain-language summaryIntrigue 65 / 100

Sevoflurane is the inhalational anesthetic of choice for pediatric mask induction, owing to its non-pungent character and pleasant odor that allow children to breathe down to anesthesia without IV access first. Synthesized by Ross Terrell at Travenol in 1968, brought to clinical use in Japan in 1990, FDA-approved in 1995 (Ultane). Blood-gas partition coefficient of 0.65 gives faster kinetics than isoflurane and a favorable cardiovascular profile with preserved cardiac output. Mechanism mirrors other halogenated ethers: GABA-A potentiation, K2P channel activation, glycine and NMDA modulation. The classical concern is Compound A, a degradation product formed when sevoflurane reacts with CO2 absorbents at very low fresh gas flows; nephrotoxic in rats but not demonstrated in humans within recommended flow limits. Workhorse modern volatile. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

49/100

Clinically dominant inhalational anesthetic with settled evidence but limited novelty as a research target

Look, sevoflurane is genuinely excellent at what it does. The clinical case is settled: low blood-gas partition coefficient (0.65), zero airway pungency, preserved cardiac output, and thirty-plus years of FDA-sanctioned use make it the dominant agent for pediatric mask induction and a reliable maintenance anesthetic for a reason. But “excellent clinical drug” and “compelling research target” are different things, and for a research library those distinctions matter a lot.

The mechanism story is familiar territory. GABA-A positive allosteric modulation, K2P channel activation, NMDA and glycine receptor involvement — this is the standard volatile anesthetic toolkit, shared with isoflurane, desflurane, and the rest of the halogenated ether class. There’s nothing mechanistically surprising here. The deeper question of why these compounds produce unconsciousness at a biological level remains genuinely open, and thats interesting, but sevoflurane isnt the primary probe you’d reach for to answer it. It’s achiral, well-characterized, and the CYP2E1 metabolism story (hexafluoroisopropanol, inorganic fluoride) is textbook at this point.

Where sevoflurane does generate real research traction is in anesthetic preconditioning biology. The compound confers cardiac and possibly neuroprotective preconditioning through mechanisms overlapping with ischemic preconditioning: reactive oxygen species signaling, mitochondrial K-ATP channels, PKC activation pathways. There’s a legitimate multi-center clinical literature here from cardiac surgery contexts. The Compound A nephrotoxicity story — CYP-mediated degradation in CO2 absorbents, definitively nephrotoxic in rats, not demonstrated in humans within clinical flow limits — remains a pharmacologically interesting species-specificity question that still doesnt have a clean mechanistic answer, and thats actually a genuine probe opportunity for researchers working on intrarenal CYP biology.

What we like: the evidence base is enormous by research library standards. Sevoflurane isnt guesswork. The cancer-outcomes literature — examining whether anesthetic choice during oncologic surgery affects tumor recurrence through immune modulation — is a live and contested area where sevoflurane appears in multiple ongoing trials, mostly contrasted against propofol-based TIVA. That’s a real open question with a real translational angle.

What we don’t like: for most bench programs, this is a procedural compound. It’s indispensable in animal surgery suites, but that’s utility, not novelty. Researchers aren’t designing studies to discover something new about sevoflurane — they’re using it so the animal stays still. That relationship is fundamentally different from what should sit at the top of a research library. Honest placement: strong reference compound, meaningful procedural tool, but not the kind of target that should be pulling investigator attention away from mechanisms that are actually unsettled.

Novelty: 18
Mechanism promise: 28
In-category differentiation: 52
Evidence quality: 82
Translational signal: 80
Research bench value: 55

Rationale Sevoflurane scores high on evidence quality and translational signal because it is a thirty-year FDA-approved clinical standard, but novelty and mechanism are both low: it shares the standard volatile anesthetic toolkit (GABA-A PAM, K2P, NMDA) with its class and brings no genuinely new biology. Differentiation credit is real but narrow, limited to its non-pungency and pediatric induction dominance within the inhalational class.

Halogenated ether volatile general anesthetic

A non-pungent fluorinated methyl isopropyl ether with a low blood-gas coefficient enabling fast induction and the dominant inhalational agent for pediatric mask induction.

Abstract

Sevoflurane (fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; CAS 28523-86-6; molecular formula C4H3F7O; molecular weight 200.05) is a fluorinated methyl isopropyl ether volatile anesthetic synthesized by Ross Terrell at Travenol Laboratories in 1968, brought to clinical use in Japan in 1990, and approved by the FDA in 1995 (Ultane, Sojourn). The minimum alveolar concentration (MAC) at age 40 is 1.8 percent in oxygen; the blood-gas partition coefficient is 0.65, faster than isoflurane (1.4) but slower than desflurane (0.42). The non-pungent character and absence of airway irritation make sevoflurane the agent of choice for inhalational induction of anesthesia, particularly in pediatric patients where intravenous access is established after induction. Mechanism parallels other halogenated ethers (GABA-A positive allosteric modulation, K2P channel activation, glycine and NMDA effects); the agent is achiral. Hepatic metabolism via CYP2E1 produces hexafluoroisopropanol and inorganic fluoride; the fluoride concentrations approach the historical nephrotoxic threshold associated with methoxyflurane (50 micromolar plasma) during prolonged exposure but published clinical data have not demonstrated nephrotoxicity in humans even with extended cases, attributed to the absence of intrarenal defluorination. The principal residual concern is degradation of sevoflurane in carbon dioxide absorbents (soda lime, Baralyme) at low fresh gas flows producing Compound A, which is nephrotoxic in rats but lacks demonstrated human renal injury within recommended fresh gas flow limits (1 to 2 L/min). Cardiovascular profile is favorable with preserved cardiac output, modest reduction in systemic vascular resistance, and minimal coronary steal physiology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1302Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-1302

Sevoflurane

Abstract

Read the full monograph